EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models

Ondrej Uher, Katerina Hadrava Vanova, Rachael Labitt, Katerina Petrlakova, Juan Ye, Herui Wang, Michal Masarik, Milan Jakubek, Jan Zenka, Zhengping Zhuang, Karel Pacak

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Ondrej Uher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Immunotherapy, Neoplasm Recurrence, Local, Melanoma, Experimental. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Ministerstvo Školství, Mládeže a Tělovýchovy, National Institutes of Health, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant immunotherapy represents a pioneering approach in the preoperative treatment of cancer, providing new strategies for tumor reduction and improved patient outcomes by modulating the immune response. This study investigated neoadjuvant immunotherapy using intratumoral administration of mannan-BAM, Toll-like receptor ligands, and anti-CD40 antibody (MBTA therapy) followed by surgery in murine models of MTT pheochromocytoma, B16-F10 melanoma, and 4T1 and E0771.lmb mammary carcinomas. In the MTT pheochromocytoma model, it was found that neoadjuvant MBTA therapy followed by surgery could prevent the development of distant metastases in 100% of treated animals, compared to a 60% mortality rate in the control group due to metastatic disease after surgery. These outcomes were achieved even in tumors three times larger than those in the control group. In the aggressive 4T1 model, neoadjuvant MBTA therapy resulted in slower tumor progression and a significant prolongation of survival. In the B16-F10 and E0771.lmb models, neoadjuvant MBTA therapy also protected animals from metastases development and tumor recurrence upon rechallenge with tumor cells after surgery. Transcriptomic analysis revealed enhanced effector immune cell infiltration, cytotoxicity, and antigen presentation in retransplanted tumors from MBTA-treated mice, indicating robust immune memory. Notably, the exclusion of the anti-CD40 antibody from the neoadjuvant MBTA therapy (MBT therapy) yielded comparable outcomes in protection against metastases development. These findings advocate for further investigation of intratumoral neoadjuvant MBTA therapy for immunologically "cold" tumors, including those at high risk of metastases or recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyImmunotherapyNeoplasm Recurrence, LocalMelanoma, ExperimentalMammary Neoplasms, ExperimentalAnimalsFemaleMiceMice, Inbred C57BLCell Line, TumorCD40 AntigensMice, Inbred BALB CDisease Models, AnimalNeoplasm Metastasis

Stichwörter der Autor:innen

4T1E0771.lmbImmunotherapyIntratumoralMelanomaNeoadjuvantPheochromocytoma

Substanzen

CD40 Antigens

Autor:innen und Institutionen

  • Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA.
  • Research Animal Management Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA.
  • Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, USA; Department of Pathological Physiology, Faculty of Medicine, Masaryk Univers…
  • Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD, USA.
  • Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; BIOCEV (Biotechnology and Bi…
  • BIOCEV (Biotechnology and Biomedicine Center in Vestec), First Faculty of Medicine, Charles University, Vestec, Czech Republic; Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Char…

Förderung

  • Ministerstvo Školství, Mládeže a Tělovýchovy
  • National Institutes of Health
  • National Cancer Institute
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Uher, O., Hadrava Vanova, K., Labitt, R., Petrlakova, K., Ye, J., Wang, H., Masarik, M., Jakubek, M., Zenka, J., Zhuang, Z., & Pacak, K. (2025). Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217464

Vancouver

Uher O, Hadrava Vanova K, Labitt R, Petrlakova K, Ye J, Wang H, et al. Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217464

BibTeX
@article{Uher2025,
  author = {Uher, Ondrej and Hadrava Vanova, Katerina and Labitt, Rachael and Petrlakova, Katerina and Ye, Juan and Wang, Herui and Masarik, Michal and Jakubek, Milan and Zenka, Jan and Zhuang, Zhengping and Pacak, Karel},
  title = {Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217464}
}
Kostenlos starten →